ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Shire Boosts R&D In Rare Diseases

by Michael McCoy
November 26, 2012 | APPEARED IN VOLUME 90, ISSUE 48

The British drug company Shire is increasing its rare disease research efforts. With Boston Children’s Hospital, Shire has formed a three-year rare pediatric disease collaboration. After making a payment to the hospital, Shire will have the right to fund selected research programs and an option to license them. Separately, Shire has entered a research pact with the Italian charity Fondazione Telethon on 13 undisclosed rare diseases. Shire will provide $22 million in funding to the charity over five years. And Shire is launching a report to gauge the health, psychosocial, societal, and economic impact of rare diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment